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Long-term cognitive trajectories and
heterogeneity in patients with schizophrenia
and their unaﬀected siblings
Islam MdA, Habtewold TD, van Es FD, Quee PJ, van den Heuvel ER,
Alizadeh BZ, Bruggeman R. Long-term cognitive trajectories and
heterogeneity in patients with schizophrenia and their unaﬀected
siblings.
Objective: This study aimed to assess the heterogeneity and stability of
cognition in patients with a non-aﬀective psychotic disorder and their
unaﬀected siblings. In addition, we aimed to predict the cognitive
subtypes of siblings by their probands.
Method: Assessments were conducted at baseline, 3 and 6 years in 1119
patients, 1059 siblings and 586 controls from the Genetic Risk and
Outcome of Psychosis (GROUP) study. Group-based trajectory
modeling was applied to identify trajectories and clustered multinomial
logistic regression analysis was used for prediction modeling. A
composite score of eight neurocognitive tests was used to measure
cognitive performance.
Results: Five stable cognitive trajectories ranging from severely altered
to high cognitive performance were identiﬁed in patients. Likewise, four
stable trajectories ranging from moderately altered to high performance
were found in siblings. Siblings had a higher risk of cognitive alteration
when patients’ alteration was mild (OR = 2.21), moderate (OR = 5.70),
and severe (OR = 10.07) compared with patients with intact cognitive
function. The familial correlation coeﬃcient between pairs of index
patients and their siblings was 0.27 (P = 0.003).
Conclusions: The cognitive proﬁles identiﬁed in the current study might
be suitable as endophenotypes and could be used in future genetic
studies and predicting functional and clinical outcomes.
Md. A. Islam1,2,3,
T. D. Habtewold1,2 ,
F. D. van Es1, P. J. Quee1,4,
E. R. van den Heuvel2,5,
B. Z. Alizadeh1,2,† ,
R. Bruggeman1,6,† , GROUP
Investigators‡
Signiﬁcant outcomes
• To our knowledge, this is the ﬁrst large-scale study to report cognitive trajectories in patients with psy-
chosis (probands) and their unaﬀected siblings.
• We identiﬁed ﬁve stable cognitive trajectories in probands: ‘severely altered’, ‘moderately altered’,
‘mildly altered’, ‘normal’, and ‘high performer’. Similarly, four stable cognitive trajectories were
identiﬁed in healthy siblings: ‘moderately altered’, ‘mildly altered’, ‘normal’, and ‘high performer’.
• The cognitive trajectory of probands signiﬁcantly predicted the cognitive trajectory of siblings. The intr-
aclass correlation (ICC) between pairs of siblings and probands was 0.27.
Limitations
• Selection and attrition bias may be evident as controls were selected by random mailing and study par-
ticipants dropped out of the study respectively.
• The prediction of a moderately altered group of siblings by high cognitive performer group of patients
was ambiguous and unstable due to low frequency.
• Eight cognitive tests were used in this study; therefore, including other tests may lead to diﬀerent trajec-
tories with diﬀerent predictions.
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Introduction
Schizophrenia spectrum disorders consist of multi-
ple symptom dimensions, caused by the interaction
of genetic, environmental, and internal factors (1).
One of these dimensions is cognitive alteration
which is present in 75–80% of the patients (2) and
which has been demonstrated to be a predictor of
symptomatic and functional outcome (e.g., work-
ing activity, daily living activity) (3–7). Evidence on
whether cognitive alteration precedes schizophre-
nia or cognitive function deteriorated after the
occurrence of schizophrenia is mixed (8–10). The
most aﬀected cognitive functions are episodic and
working memory, attention, verbal ﬂuency, execu-
tive function, problem-solving, processing speed,
and social cognition (11).
Cognitive function can be measured based on the
actual change in patient’s cognitive performance
over time or deviation from the familial cognitive
performance (12). Although cognitive alteration in
patients with schizophrenia is heterogeneous, the
majority of the studies shows that cognitive alter-
ation within an individual with schizophrenia is
stable and persistent over time (13–15). On the
other hand, in patients with ﬁrst-episode psychosis,
studies investigating the trajectories of diﬀerent cog-
nitive performance suggested an improvement over
time (16, 17). Given the substantial diﬀerence across
patients, clustering methods using latent class analy-
sis, hierarchical mixture model and group-based tra-
jectory modeling have been used to identify
cognitive trajectories in a diﬀerent group of popula-
tion (18). To date, two to ﬁve cognitive trajectories
have been identiﬁed in patients with psychosis who
diﬀer in terms of demographic and clinical charac-
teristics (19–23). Cognitive alteration is also com-
mon in unaﬀected siblings, but to a lesser extent,
and subtyping is relevant to identify meaningful
homogeneous trajectories (13, 24–28). In our previ-
ous cross-sectional study, we demonstrated three
subtypes of cognitive alteration (i.e., normal, mixed,
and impaired) in siblings (23).
Cognitive alteration in patients with schizophre-
nia can be associated with cannabis use (29), nega-
tive and schizotypy symptoms (30, 31) and medical
comorbidities such as diabetes mellitus, hyperten-
sion, dyslipidemia, and obesity (32). Other inﬂu-
encing factors include decreased gray matter
density in the cerebellum (33), reduced blood omega-
3 fatty acids (34), N-methyl-d-Aspartate receptor
(NMDAR) hypofunction (35) and inﬂammation
(36). In siblings, cognitive alteration can be attributed
to shared genetic (37–39) and socio-environmental
risk factors with the patients (13). Cognitive alter-
ation can be considered an inheritable trait of
schizophrenia, which itself has a heritability (h2) 31–
62% (40–42). Some family-based studies have also
found a higher rate of cognitive alteration in unaf-
fected relatives of individuals with schizophrenia than
in the general population (43). These ﬁndings support
the assertion that cognitive dysfunction can be desig-
nated an important endophenotype of schizophrenia.
This is important for future large-scale twin/family-
based and SNP-based heritability studies.
Schizophrenia is invariably acknowledged to be
an extremely heterogeneous disorder. Yet, eﬀorts
to ﬁnd meaningful subtypes (cognitive, clinical, or
neurobiological) have been manifold but they
remain of questionable success. Possible explana-
tions for the unsuccessful subtyping are use of sin-
gle cognitive test or domain (e.g., intelligence
quotient (IQ)) based on mean values that do not
take into account heterogeneity, uncertainty on
whether cognitive alteration is general or speciﬁc,
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limited number of longitudinal studies with short
follow-up period, small sample size, and limited
use of data from healthy siblings and controls (13,
44, 45). Therefore, to our knowledge, this is the
ﬁrst large-scale long-term study which included
cognitive trajectory modeling for both patients and
their unaﬀected siblings.
The aim of this study was twofold. First, we
examined ways to unravel the heterogeneity of
neurocognition, by classifying patients and siblings
respectively into diﬀerent subgroups based on the
course of composite overall cognition scores over
time, separately from each other, based on eight
neurocognitive test parameters. After determining
meaningful subgroups of patients and siblings, we
aimed to predict the cognitive subtypes of siblings
by subtypes of patients within a family using sib-
ling-patient analyses. Given the advancement of
clustering technique and increasing trend of identi-
ﬁed subgroups of patients with schizophrenia
(19–23), we hypothesized that more meaningful
trajectories can be discovered. There has been a
substantial controversy regarding the course of
cognitive alliteration in patients with schizophrenia
and their unaﬀected siblings (13). The accumulated
body of evidence (13) shows that the course of cog-
nitive function in schizophrenia is inconsistent
while some studies show stability or improvement,
others support deterioration of cognitive function.
In this study, we hypothesized that the cognitive
trajectory over time is stable. In addition, we
hypothesized the probands cognitive trajectory
predict siblings cognitive alteration trajectory.
Methods
Study setting and population
The current study was performed within the frame-
work of the Genetic Risk and Outcome of
Psychosis (GROUP) project, a longitudinal multi-
center cohort study in the Netherlands and
Belgium. Patients with non-aﬀective psychotic dis-
order based on DSM-IV (46), age between 16 and
50 years and good command of the Dutch lan-
guage were included. Siblings were included if they
(i) were between 16 and 50 years, (ii) had a good
command of the Dutch language, and (iii) had no
lifetime psychotic disorder. Controls were included
if they did not have a lifetime diagnosis of psy-
chotic, bipolar or current depressive disorder. In
addition, controls were included if they did not
have a ﬁrst or second degree relative with psy-
chotic disorder (47). The procedure of recruitment,
informed consent, ethical approval, and population
characteristics at baseline have been described in
detail elsewhere (48).
Sample size calculation
There was no formal sample size calculation for tra-
jectory modeling analysis. However, Formann esti-
mated that the minimum sample size for latent class
analysis is 2k subjects, where k is the number of vari-
ables (49). Therefore, we need at least 2k = 28 = 256
subjects in our study, which we satisfy by large. To
establish a power of 93% (a = 0.05) in a case–con-
trol and a case-sibling longitudinal study design (s-
tandard deviation = 0.15) on cognitive function, at
least 1000 patients, 1000 siblings, and 350 controls
are needed. In the current study, 1119 patients, 1059
siblings, and 586 healthy controls were participated
at baseline, 3 years, and 6 years follow-up (48).
Assessment of neurocognition
Task selection was based on cognitive domains
that have been shown to be altered in schizophre-
nia (50). The cognitive battery has been described
in detail elsewhere (28). This study assessed
Table 1. Measures of neurocognition
Cognitive domains Group tests Outcome measure
Sustained attention and vigilance Continuous performance test (CPT-HQ)
(CPT performance and CPT variance)
An efficiency score [(accuracy/reaction time) 91000] was created, in which accuracy
was measured as the total number of hits (range 0–28) minus the total number of
errors (range 0–28), divided by 28. If this calculation of accuracy was non-positive
(i.e., the number of errors equaled or exceeded the number of hits), then the accuracy
was set equal to 0.005. This score was referred to as ‘CPT performance’. Intra-individual
variability in reaction time on the CPT was also evaluated (CPT variance), using the
standard deviation score of the subject’s mean response time on the hit trials (23, 51).
Verbal learning and memory Word Learning Task (WLT)
(Immediate and delayed recall)
Immediate recall (total score of three consecutive trials of 15 words learning) and
‘Delayed recall’ was assessed after 20 min delay
Global cognitive functioning
Processing speed Digit symbol substitution Total raw score (0–133)
Verbal comprehension Information Total raw score (0–28)
Working memory Arithmetic Total raw score (0–22)
Problem-solving and Visuospatial abilities Block design Total raw score (0–68)
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neurocognitive performance using eight assessment
tools. Table 1 shows the list of cognitive domains,
their corresponding tests, and outcome measures.
We calculated a composite neurocognitive score
based on the following eight neurocognitive mea-
sures: CPT performance, CPT variance, immediate
recall, delayed recall, digit symbol substitution,
information, arithmetic, and block design. Subse-
quently, linear regression analyses were conducted
for each time point. The control subjects score was
used to obtain age- and gender-stratiﬁed neurocog-
nitive tests z-score for both patients and siblings.
Finally, the composite score for patients and sib-
lings was computed by averaging z-score of all
eight tests.
Assessments of sociodemographic and clinical variables
The sociodemographic variables were age of par-
ticipants, age of onset of psychosis educational sta-
tus, gender, and ethnicity. According to Verhage
(52), educational status was evaluated as a contin-
uous variable. Psychotic disorder was assessed by
the Comprehensive Assessment of Symptoms and
History (CASH) (53) or Schedules for Clinical
Assessment in Neuropsychiatry (SCAN) question-
naire (54, 55). Level of premorbid functioning was
assessed using the Premorbid Adjustment Scale
(PAS) (56). Positive and negative symptoms of
schizotypy were measured using the Structured
Inventory for Schizotypy-Revised (SIS-R) (57).
The SIS-R is a reliable and valid semistructured
interview for rating schizotypal sign and symptoms
administered in unaﬀected siblings and healthy
controls (57). Frequency and distress of psychotic
experiences were measured with the Community
Assessment of Psychic Experiences (CAPE) ques-
tionnaire (58). The CAPE is a 42-item reliable and
valid self-report questionnaire to assess psychotic-
like experiences in the community and in individu-
als at an increased risk for developing psychosis
(i.e., siblings in our study) and in healthy controls
(58). Symptom severity in patients was assessed
with the positive and negative syndrome scale
(PANSS) (59, 60).
Data analysis and statistical modeling
Descriptive statistics. Patients, siblings, and con-
trols diﬀerence in sociodemographic characteristics
at baseline were tested using univariate analyses.
For gender and ethnicity, Pearson’s chi-squared test
was used. Due to the family structure data, linear
mixed eﬀects models using family as a random
eﬀect were applied to all continuous variables (e.g.,
sociodemographic, clinical, and cognitive tests) to
test for diﬀerences between the groups. Maximum
likelihood (ML) method was used to estimate the
model parameters and Type-III (overall) tests of ﬁxed
eﬀects were used to test for diﬀerences between
groups. Signiﬁcant diﬀerences were followed by pair-
wise post hoc comparisons between groups. Addition-
ally, Pearson’s correlation coeﬃcients between cogni-
tive performances were computed for patients and
siblings to explore the possible predictive relationship.
Subtyping and trajectory modeling. Subtyping is the
level of overall cognitive functioning across time
whereas trajectory is the pattern (e.g., stable, ﬂuc-
tuating, decline, or improvement) of overall cogni-
tive functioning or the speciﬁc cognitive domain/
test. Group-based trajectory modeling (GBTM)
(61–64) was conducted to identify clusters of
patients and siblings with a similar pattern of neu-
rocognitive function over time. The neurocognitive
composite score was used as a dependent variable
and follow-up time (baseline, 3 and 6 years) as an
independent variable. First order linear and second
order quadratic polynomial models were ﬁtted
assuming that individual diﬀerences in trajectories
could be summarized by a ﬁnite set of polynomial
functions of time. To determine the number of
clusters and the best-ﬁtting model, a sequential
approach was applied where the number of clusters
is increased by one. The less complex model (i.e.,
less trajectory groups) was compared with the
complex model (i.e., more groups) using the Baye-
sian information criterion (BIC) (65) and logged
Bayes factor (2*DBIC), where DBIC = BIC (com-
plex) – BIC (less complex) (66, 67) and where the
logged Bayes factor (2*DBIC) would indicate triv-
ial (0–2), positive (2–6), strong (6–10) or very
strong (>10) evidence for the null hypothesis that
the less complex model is the best ﬁt.
First, a single quadratic polynomial trajectory
model was examined. If the quadratic term was
not signiﬁcant, the model was repeated with a lin-
ear trajectory to determine the BIC value. If the
quadratic component in one trajectory model was
signiﬁcant, the quadratic two-trajectory model was
performed. Next, the BIC value of the appropriate
two-trajectory model was compared to the BIC
value of the appropriate one-trajectory model. The
process was repeated by increasing the number of
trajectories until the best-ﬁt model was found (68).
The trajectory modeling was stopped when the
DBIC became a negative value. GBTM can handle
missing data in the cognition score using ML esti-
mation method to create asymptomatically unbi-
ased parameter estimates under the assumption of
data missingness at random (69, 70). We also
checked the drop-out model which includes a
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logistic model of drop-out probability per period to
interrogate whether the attrition rates signiﬁcantly
aﬀected/biased the cognitive trajectory group mem-
bership probabilities (71). For each group, 0 = con-
stant attrition rate, 1 = depends on the previous
response (i.e., baseline) and 2 = depends on the two
previous responses (i.e., baseline and 3 years).
Comparison among cognitive subtypes. Diﬀerences
between the subgroups of patients and siblings in
all continuous variables were investigated using
linear mixed eﬀect models taking familial relation-
ship into account. Type-III (overall) tests of ﬁxed
eﬀects were used to test group diﬀerences. If these
were signiﬁcant, pair-wise comparison was done
using Dunnett’s method (taking the most normal
cognitive proﬁle as a reference group). For gender
and ethnicity, the Pearson’s chi-squared test was
used to test the diﬀerence between subgroups of
patients and siblings.
Predicting cognitive subtypes of siblings using subtypes
of probands. We considered sibling subtype (multi-
category) as a dependent variable and patient sub-
type (multi-category) as an independent variable.
The probability of concordance, probability of dis-
cordance and Somers’ D statistic (72) were com-
puted on the pairs of subtypes of patients and
siblings. A pair of patients-siblings subtype was
reported concordant if the larger value of subtypes
of patients was paired with the larger value of sub-
types of siblings, and discordant if the larger value
of subtypes of patients was paired with the smaller
value of subtypes of siblings. Somers’ D of subtypes
of siblings, with respect to subtypes of patients, was
deﬁned as the diﬀerence between the two condi-
tional probabilities of concordance and discordance.
Clustered multinomial logistic regression analy-
sis was conducted taking into account family as a
random eﬀect given that siblings and patients
belong within the same family. PROC NLMIXED
in SAS (Statistical Analysis System) was applied to
determine the predictive relationship between sub-
types of patients and siblings. An adaptive Gaus-
sian quadrature with ten quadrature points was
speciﬁed to integrate out the random eﬀect of the
likelihood function (73, 74) and to estimate the
parameters (i.e., subtypes of patients) and their
standard errors. The intra-cluster correlation coef-
ﬁcient (ICC) was calculated to estimate the familial
correlation between pairs of unaﬀected siblings
and probands in the same family. The ICC was cal-
culated as ICCFamily = var(family)/(var(family) +
p2/3), where var(family) is the variance of random
eﬀect and p is 3.14159. A two-tailed test at
P < 0.05 was considered as statistical signiﬁcant
throughout the analyses. For pair-wise compar-
isons, Bonferroni correction for multiple testing
was done and statistical signiﬁcance was deter-
mined at P < 0.05/20. All analyses were performed
using SAS version 9.4. In this study, GROUP data
version 4.00 was used.
Results
Descriptive of the study population
At baseline, patients, siblings, and controls signiﬁ-
cantly (P < 0.001) diﬀered by sociodemographic,
cognitive, and clinical variables. Pair-wise compar-
isons revealed that the diﬀerences were signiﬁcant
between patients and controls as well as siblings
and controls. Patients and siblings cognitive per-
formance was low compared to controls. Addition-
ally, cognitive performances of patients were
found to be signiﬁcantly lower than the perfor-
mances of their unaﬀected siblings (Table 2).
Correlation between all cognitive tests was signif-
icant in patients and siblings except the correlation
between CPT performance and block design, arith-
metic and information in siblings (Table S1–S2).
Cognitive subtypes and trajectories
A ﬁve-group cognitive trajectory model for patients
and four-group trajectory model for siblings were
very strongly favoured for overall cognitive scores
(z-scores) according to the smallest BIC and the
logged Bayes factor (Table S3). In patients, the
value of logged Bayes factor was 17.34 (>10), thus
favouring the ﬁve-cluster model over a six-cluster
model. In siblings, the value of logged Bayes factor
was 94.62 (>10), favouring the four-trajectory
model over a ﬁve-cluster model (Table S3). Param-
eter estimates of linear and quadratic polynomial
time functions of trajectory modeling and drop-out
model presented in Tables S4 and S5. The drop-out
of patients and unaﬀected siblings did not signiﬁ-
cantly aﬀect/biased their cognitive trajectory group
membership probabilities.
Figures 1a and b displays cognitive trajectories
of patients and their siblings over 6 years respec-
tively. The cognitive trajectories in patients were
labeled as ‘severely altered’, ‘moderately altered’,
‘mildly altered’, ‘normal’, and ‘high performer’.
Similarly, the trajectories in siblings were labeled
as ‘moderately altered’, ‘mildly altered’, ‘normal’,
and ‘high performer’. All initial neurocognitive
proﬁles for patients and siblings were stable over
time. Severe and moderate groups were identiﬁed
based on a broad-based cognitive alteration of, on
average, about 1 SD below the normal cognitive
5
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trajectory across a range of cognition composite
score. We showed 26.7% of patients had a normal
cognitive function, 30.4% mild, 28.4% moderate,
and 10.7% severe cognitive alterations. Likewise,
37.6% of siblings showed a normal cognitive func-
tioning, 25.1% mild and 13.0% moderate cognitive
alteration. Three point eight percent of patients and
24.2% of siblings had higher cognitive functioning
compared with the mean level of the normal cogni-
tive subtype. Patients in this cluster showed a subtle
signiﬁcant decline over time (Fig. 1a), whereas the
pattern was stable for siblings (Fig. 1b).
Comparison of cognitive subtypes on all baseline characteristics
Cognitive subtypes of patients were compared based
on cognitive measures, demographic characteristics,
and clinical variables. Patients with normal cogni-
tive proﬁle diﬀered signiﬁcantly from other patient
subgroups in education, IQ, premorbid function-
ing, and psychotic symptoms. The detailed pair-
wise comparisons on cognitive subtypes of patients
have been shown in Table 3.
Diﬀerences between normal cognitive subtype
and other subtypes of siblings were statistically
signiﬁcant with regard to age, gender, education,
ethnicity, IQ, premorbid functioning, positive
symptoms, frequency of psychotic experiences, and
all cognitive performances except CPT variance.
The detailed pair-wise comparisons on cognitive
subtypes of siblings have been shown in Table 4.
Association of cognitive subtypes of patients and siblings
In the sibling-patient pair analysis, we generated
1070 pairs of aﬀected and unaﬀected siblings. The
number of pairs was more than 1059 because we
paired multiple unaﬀected siblings with their single
aﬀected sibling or multiple aﬀected siblings with
their single unaﬀected sibling within a family. The
contingency table of the subtypes of patients and
siblings is presented in the Table S6. Somers’ D





comparisonControls (n = 586) Siblings (n = 1059) Patients (n = 1119)
Age 30.42 (10.58) 27.84 (8.28) 27.58 (7.94) F = 22.8, P < 0.001 Sibs<Ctrs,Pts<Ctrs
Age of onset . . . . . . 23.69 (7.59) . . . . . .
Gender, male 45.90 45.51 76.14 v² = 254.1, P < 0.001 Sibs<Ctrs<Pts
Education (Verhage)a 5.41 (1.78) 5.07 (2.11) 4.04 (2.05) F = 128.5, P < 0.001 Pts<Sbs<Ctrs
Ethnicity, Dutch 92.12 83.24 79.22 v² = 45.2, P < 0.001 Pts<Sbs<Ctrs
Estimated IQb 109.75 (15.08) 102.76 (15.60) 94.99 (16.12) F = 185.6, P < 0.001 Pts<Sbs<Ctrs
Overall score PASc 1.13 (0.59) 1.13 (0.66) 1.98 (0.88) F = 439.0, P < 0.001 Sbs<Pts, Pts<Ctrs
SIS-Rd
Positive 0.31 (0.35) 0.38 (0.42) . . . F = 15.4, P < 0.001 Ctrs<Sbs
Negative 0.24 (0.22) 0.27 (0.26) . . . F = 9.0, P = 0.002 Ctrs<Sbs
PANSS 5-factor
Positive . . . . . . 13.90 (6.55) . . . . . .
Negative . . . . . . 15.00 (6.64) . . . . . .
Disorganization . . . . . . 16.77 (6.27) . . . . . .
Excitement . . . . . . 12.05 (4.05) . . . . . .
Emotional distress . . . . . . 15.82 (5.73) . . . . . .
CAPE (Positive dimension)e
PE Frequency 0.19 (0.17) 0.21 (0.20) 0.67 (0.49) F = 566.5, P < 0.001 Sbs<Pts, Pts<Ctrs
PE Distress 0.43 (0.45) 0.46 (0.48) 1.26 (0.69) F = 531.0, P < 0.001 Sbs<Pts, Pts<Ctrs
Cognitive Performance
CPT performancef 246.36 (54.78) 243.70 (57.86) 220.82 (62.14) F = 52.0, P < 0.001 Pts<Sbs, Ctrs<Pts
CPT variance (ms)g 72.76 (28.28) 75.80 (28.44) 92.99 (36.51) F = 108.4, P < 0.001 Sbs<Pts, Pts<Ctrs
Block designh 46.55 (14.16) 44.87 (15.07) 40.42 (16.99) F = 39.2, P < 0.001 Pts<Sbs<Ctrs
Digit symboli 84.01 (14.58) 79.21 (15.39) 65.41 (16.27) F = 379.9, P < 0.001 Pts<Sbs<Ctrs
Arithmeticj 15.32 (4.16) 13.86 (4.43) 12.27 (4.79) F = 93.1, P < 0.001 Pts<Sbs<Ctrs
Informationk 18.84 (4.67) 16.83 (5.22) 16.77 (5.47) F = 31.5, P < 0.001 Sbs<Ctrs, Pts<Ctrs
Immediate recalll 28.47 (5.37) 26.89 (5.77) 22.94 (6.09) F = 224.5, P < 0.001 Pts<Sbs<Ctrs
Delayed recallm 9.74 (2.70) 9.33 (2.64) 7.53 (2.87) F = 181.6, P < 0.001 Pts<Sbs<Ctrs
*Table presents means (SD) or %; Empty (. . .) row or column means no measurements in the respective group or variable; aEducation (Verhage): range 0 (no education), 3–5
(school diploma) to 8 (university degree); bIQ: Wechsler Adult Intelligence Scale-III (WAIS-III), short form; cPAS: Premorbid Adjustment Scale; dSIS-R: Structured Inventory for
Schizotypy – Revised; eCAPE: Community Assessment for Psychic Experiences; PE frequency and distress: Frequency of positive psychotic experiences and amount of distress of
these PE; fCPT performance: Continuous performance test HQ, performance index, gCPT variance (ms): CPT-HQ variance in reaction time (ms); hBlock design: WAIS-III Block
design; iDigit symbol: WAIS-III Digit symbol substitution test; jArithmetic: WAIS-III Arithmetic; kInformation: WAIS-III Information; lImmediate recall: Word Learning Task (WLT)
immediate recall; mDelayed recall: WLT Delayed recall. For the PAS, higher scores reflect poorer premorbid adjustment; Ctrs: Controls; Sibs: Siblings; Pts: Patients; Pair-wise
group comparison explains which group has significantly different values on the measurements; ϮP < 0.05/20 was considered as statistically significant.
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value for the association between cognitive sub-
types of patients and subtypes of siblings amongst
the 1070 sib-pairs was 0.29. A positive value of
Somers’ D indicates that the siblings have better
cognitive scores than their probands.
Since the cell frequency of moderately altered
subtype in the sibling coupled with high cognitive
performance in the patient was zero (Table S6), we
combined the high cognitive performer group of
patients with the normal cognitive group. The
combined normal and high performer group of
patients was considered as the reference group.
Table S7 presents the association between cog-
nitive subtypes of patients and siblings. Overall,
cognitive subtypes of patients signiﬁcantly pre-
dicted the siblings’ subtypes. Here, we present a
risk of an unaﬀected sibling to be grouped in any
of mildly altered, moderately altered, and severely
altered groups given the cognitive trajectory of
their corresponding aﬀected sibling. The familial
correlation was 0.27 at a signiﬁcance level of
P = 0.003.
We observed that unaﬀected sibling with a
severely and moderately altered patients was at risk
of having mild alterations with an odds ratio (OR)
of 2.56 (95% CI 1.26–5.18) and 1.83 (95% CI 1.12–
2.98) respectively. However, mild cognitive alter-
ations in patients did not predict mild alterations in
their unaﬀected siblings (OR = 0.86, P = 0.54).
Compared with siblings of patients with intact cog-
nitive function, siblings were at risk of moderate
alteration if their probands cognitive alteration was
mild (OR = 2.21, 95% CI 1.05–4.64), moderate
(OR = 5.70, 95% CI 2.77–11.70), or severe
(OR = 10.07, 95% CI 4.15–24.44). Subsequently,
siblings had a low likelihood of having high cogni-
tive performance if patients were severely
(OR = 0.26, 95% CI 0.09–0.63) or moderately
(OR = 0.39, 95% CI 0.24–0.64) altered and a low






















































































Cognitive trajectories for patients(a)










Fig. 1. (a) Cognitive trajectories for
patients (n = 1119), (b) Cognitive
trajectories for siblings (n = 1059).
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95%CI 0.24–0.59) when the probands performance
was normal or high. In general, unaﬀected siblings
of patients with severe alteration were likely to
develop moderate to mild cognitive alterations.
Discussion
To our knowledge, this is the ﬁrst large-scale study
to report cognitive trajectories in patients with
non-aﬀective psychosis (probands) and their unaf-
fected siblings. We identiﬁed ﬁve stable and persis-
tent cognitive trajectories within the proband
group: ‘severely altered’, ‘moderately altered’,
‘mildly altered’, ‘normal’, and ‘high performer’.
Similarly, we identiﬁed four stable and persistent
trajectories among unaﬀected siblings: ‘moderately
altered’, ‘mildly altered’, ‘normal’, and ‘high per-
former’. The normal subgroup diﬀered signiﬁcantly
from the other subgroups in sociodemographic,
symptomatic, and cognitive proﬁles. Furthermore,
the cognitive trajectory of probands signiﬁcantly
predicted the cognitive trajectory of siblings, the
intraclass correlation (ICC) between pairs of sib-
lings and probands was 0.27.
In this study, the trajectory modeling demon-
strated ﬁve cognitive subgroups for patients and
four cognitive subgroups for siblings, which con-
ﬁrms the presence of distinct subgroups deﬁned by
cognitive functioning and provides further support
for cognitive heterogeneity within psychosis
patients and healthy siblings. Similarly, previous
cluster analysis studies have reported two to ﬁve
distinct subgroups in patients (19–23) and three
subgroups in healthy siblings (23). In agreement
with previous studies (75–77), approximately
69.5% of patients had poor cognitive performance
(i.e., severe, moderate, and mild alteration level).
On the other hand, 30.5% of patients had an intact
cognitive function. This ﬁnding is higher than pre-
vious studies that reported 19–28% of patients
with psychosis found to have an intact cognitive
function (20, 78–81). This discrepancy may be due
to the diﬀerence in duration of follow-up, cognitive
assessment tools, use of composite score, and level
of cognitive function at baseline.
Similar to our earlier cross-sectional study (23), a
total of 38% siblings exhibited a stable lower cogni-
tive performance (i.e., both moderate and mild
level) over the 6 years. Siblings in the moderate
altered group were more often an ethnic minority,
young, less intelligent, and with high psychotic
experiences as supported by the previous review











Age 31.4 (8.3) 27.3 (7.2) 28.0 (8.0) 27.3 (8.4) 26.8 (8.0) F = 2.5, P = 0.051 2 < 1
Age of Onset 26.2 (8.1) 23.0 (6.5) 23.2 (7.9) 22.9 (7.9) 23.0 (7.3) F = 1.4, P = 0.253
Gender, % male 74.2 77.9 74.3 77.2 75.2 v²=1.6, P = 0.816
Education (Verhage)a 5.8 (1.9) 4.9 (1.8) 4.3 (2.0) 3.3 (1.9) 2.6 (1.8) F = 49.0, P < 0.001 2 < 1; 2 > 3,4,5
Ethnicity, % Dutch 90.3 87.2 79.9 75.1 64.5 v²=30.6, P < 0.001 2 < 1; 2 > 3,4,5
IQ, Estimatedb 127.8 (10.7) 110.5 (10.4) 95.7 (8.6) 83.3 (7.7) 72.9 (6.7) F = 615.6, P < 0.001 2 < 1;2 > 3,4,5
PAS, overall scorec 1.8 (1.0) 1.8 (0.8) 1.9 (0.8) 2.1 (1.0) 2.3 (0.8) F = 9.7, P < 0.001 2 < 4,5
PANSS 5-factord
Positive 14.0 (8.2) 13.4 (5.9) 13.1 (5.9) 15.0 (7.1) 14.8 (7.7) F = 4.0, P = 0.003 2 < 4
Negative 15.1 (6.4) 13.6 (5.9) 14.3 (6.4) 16.1 (7.0) 18.0 (7.1) F = 11.1, P < 0.001 2 < 4,5
Disorganization 16.0 (6.8) 14.8 (4.9) 15.7 (5.6) 18.3 (6.6) 21.3 (7.1) F = 30.5, P < 0.001 2 < 4,5
Excitement 12.8 (5.2) 11.5 (3.5) 11.5 (3.7) 12.7 (4.4) 13.2 (4.5) F = 7.0, P = 0.001 2 < 4,5
Emotional distress 16.0 (5.7) 15.4 (5.4) 15.2 (5.5) 16.7 (5.8) 16.4 (6.8) F = 3.3, P = 0.024 2 < 4
Cognitive performance
CPT performancee 256.1 (45.7) 240.9 (52.2) 225.8 (59.6) 210.7 (56.5) 170.0 (78.8) F = 30.1, P < 0.001 2 > 3,4,5
CPT variance (ms)f 84.2 (35.3) 83.1 (31.9) 90.1 (36.0) 101.8 (37.2) 106.3 (38.9) F = 13.4, P < 0.001 2 < 4,5
Block designg 60.4 (8.8) 53.5 (10.9) 42.2 (14.3) 30.7 (13.8) 20.6 (11.0) F = 197.6, P < 0.001 2 < 1; 2 > 3,4,5
Digit symbolh 85.2 (14.6) 76.2 (14.6) 66.5 (12.5) 57.8 (12.9) 47.5 (11.7) F = 138.7, P < 0.001 2 < 1; 2 > 3,4,5
Arithmetici 18.8 (2.5) 16.2 (3.2) 13.0 (3.8) 9.1 (3.3) 6.7 (2.7) F = 264.22, P < 0.001 2 < 1; 2 > 3,4,5
Informationj 24.6 (2.3) 21.1 (3.4) 17.4 (4.3) 13.6 (4.3) 9.9 (3.5) F = 243.9, P < 0.001 2 < 1; 2 > 3,4,5
Immediate recallk 32.4 (3.8) 27.1 (4.7) 23.4 (4.7) 19.9 (4.8) 15.9 (5.0) F = 173.2, P < 0.001 2 < 1; 2 > 3,4,5
Delayed recalll 12.1 (1.8) 9.4 (2.4) 7.6 (2.4) 6.2 (2.2) 4.6 (2.0) F = 142.7, P < 0.001 2 < 1 2 > 3,4,5
*Table presents mean (SD standard deviation) or %; **Only significantly different trajectory groups are reported based on Dunnett’s adjustment. The reference group is normal
trajectory group; aEducation (Verhage): range 0 (no education), 3–5 (school diploma) to 8 (university degree); bIQ: Wechsler Adult Intelligence Scale-III (WAIS-III), short form; cPAS:
Premorbid Adjustment Scale; dPANSS: Positive and negative syndrome scale (higher scores in PAS and PANSS reflect poorer outcomes); eCPT performance: Continuous perfor-
mance test HQ, performance index, fCPT variance (ms): CPT-HQ variance in reaction time (ms); gBlock design: WAIS-III Block design; hDigit symbol: WAIS-III Digit symbol substitu-
tion test; iArithmetic: WAIS-III Arithmetic; jInformation: WAIS-III Information; kImmediate recall: Word Learning Task (WLT) immediate recall; lDelayed recall: WLT Delayed recall;
Cognitive trajectory: high performance (1) to severely altered (5); Ϯp < 0.05/20 was considered as statistically significant.
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(13). In line with the previous study (82), we
depicted that patients and siblings with mild to sev-
ere cognitive alteration performed at least 1 SD
below normal cognition. In accordance with our
hypothesis and previous studies report (13, 83, 84),
we also found cognitive trajectories in patients and
their unaﬀected siblings were stable over the 6 years
follow-up period. This is diﬀerent from other previ-
ous literature (13,16,17), which may be related to
the use of a composite score that obliterated the
change occurred in individual cognitive domain.
Negative and positive symptoms in patients with
moderately and severely altered cognition were sig-
niﬁcantly higher than in the mildly altered and
intact subgroups. This ﬁnding was consistent with
previous studies and supports the notion that psy-
chotic symptoms have been strongly associated
with cognitive alteration (19, 20, 30, 31, 85). In line
with previous ﬁndings (19, 20, 86), IQ was signiﬁ-
cantly lower in patients with mild to severe cogni-
tive alteration compared with patients with intact
cognitive function.
The positive Somers’ D value from the sib-pair
analysis showed that the proband is more likely to
show low cognitive performance than the sibling,
which implies the illness itself, medication and
motivation may have an impact on cognitive
performance. Congruent with our hypothesis, the
cognitive subtypes of the patients signiﬁcantly pre-
dicted the cognitive subtypes of siblings within the
family. The poorer the cognitive proﬁle of the
patient, the better it predicted the proﬁle of a more
cognitively altered sibling. Moreover, siblings with
a high-performance proﬁle are less predicted when
their probands are severely altered.
We found a familial correlation of 27% for cog-
nitive function, which is high compared with other
complex diseases such as depression or bipolar dis-
order and can be used in clinical practice. Of note,
this correlation represents the familial risk (which
involves genetic and shared familial environment),
as sibling designs do not allow to estimate the
extent of the genetic and shared environmental con-
tribution separately. As is evident from the litera-
ture, the neurocognitive alteration is heritable and
genetically correlated with schizophrenia (42, 87,
88). Indeed, Husted et al. showed that neurocogni-
tive traits are highly heritable in patients with
known familial schizophrenia (h2 = 31–62%) (42).
Using a large patient sample data, we uncovered
ﬁve cognition trajectories after 10 years, which sig-
niﬁes a high degree of heterogeneity is still evident
within non-aﬀective psychosis patients and war-
rants further investigation. In line with previous






comparison**1. High (n = 254) 2. Normal (n = 413) 3. Mild (n = 260) 4. Moderate (n = 132)
Age 28.6 (7.7) 27.9 (8.0) 27.8 (8.9) 26.3 (8.9) F = 5.6, P = 0.001 2 < 1
Gender, % male 55.5 43.6 41.5 40.2 v² = 14.1, P = 0.003 2 < 1; 2 > 4
Education (Verhage)a 6.1 (1.8) 5.3 (2.0) 4.5 (2.0) 3.5 (2.1) F = 62.2, P < 0.001 2 < 1; 2 > 3,4
Ethnicity, % Dutch 87.4 85.7 79.5 74.8 v² = 14.1, P = 0.003 2 < 1; 2 > 3,4
IQ, Estimatedb 120.7 (9.9) 104.9 (9.5) 92.1 (7.9) 81.9 (6.7) F = 684.7, P < 0.001 2 < 1; 2 > 3,4
PAS, overall scorec 0.9 (0.6) 1.1 (0.7) 1.2 (0.6) 1.3 (0.7) F = 13.6, P < 0.001 2 < 4, 2 > 1
SIS-Rd
Positive 0.3 (0.4) 0.4 (0.4) 0.4 (0.4) 0.5 (0.5) F = 4.2, P = 0.006 2 < 4
Negative 0.3 (0.3) 0.3 (0.2) 0.3 (0.3) 0.3 (0.3) F = 2.5, P = 0.108
CAPE (Positive dimension)e
PE Frequency 0.2 (0.2) 0.2 (0.2) 0.2 (0.2) 0.3 (0.3) F = 4.3, P = 0.006 2 < 4
PE Distress 0.4 (0.4) 0.5 (0.5) 0.5 (0.5) 0.6 (0.5) F = 2.4, P = 0.074
Cognitive performance
CPT performancef 254.9 (58.9) 245.3 (49.8) 242.4 (59.7) 220.9 (68.3) F = 9.3, P < 0.001 2 > 4
CPT variance (ms)g 70.9 (26.0) 74.6 (26.7) 80.0 (30.3) 80.2 (32.3) F = 4.8, P = 0.003 2 > 1; 2 < 3,4
Block designh 56.3 (8.4) 48.2 (12.4) 37.1 (13.8) 28.1 (11.9) F = 208.3, P < 0.001 2 < 1;2 > 3,4
Digit symboli 89.7 (11.9) 81.4 (13.0) 72.7 (14.4) 65.5 (13.8) F = 121.7, P < 0.001 2 < 1;2 > 3,4
Arithmeticj 17.7 (2.6) 14.9 (3.2) 11.5 (3.6) 8.2 (3.1) F = 318.5, P < 0.001 2 < 1; 2 > 3,4
Informationk 21.8 (3.5) 17.5 (4.0) 14.1 (3.8) 10.6 (3.6) F = 299.9, P < 0.001 2 < 1; 2 > 3,4
Immediate recalll 31.4 (4.4) 27.3 (4.9) 25.0 (5.0) 20.7 (4.8) F = 159.0, P < 0.001 2 < 1; 2 > 3,4
Delayed recallm 11.3 (2.1) 9.5 (2.4) 8.5 (2.3) 6.6 (1.8) F = 113.2, P < 0.001 2 < 1; 2 > 3,4
*Table presents mean (standard deviation) or %; **Only significantly different trajectory groups are reported based on Dunnett’s adjustment. The reference group is normal tra-
jectory group; aEducation (Verhage): range 0 (no education), 3–5 (school diploma) to 8 (university degree); bIQ: Wechsler Adult Intelligence Scale-III (WAIS-III), short form; cPAS:
Premorbid Adjustment Scale; dSIS-R: Structured Inventory for Schizotypy—Revised (higher scores in PAS and SIS-R reflect poorer outcomes); eCAPE: Community Assessment for
Psychic Experiences; PE frequency and distress: Frequency of positive psychotic experiences and amount of distress of these PE; fCPT performance: Continuous performance test
HQ, performance index, gCPT variance (ms): CPT-HQ variance in reaction time (ms); hBlock design: WAIS-III Block design; iDigit symbol: WAIS-III Digit symbol substitution test;
jArithmetic: WAIS-III Arithmetic; kInformation: WAIS-III Information; lImmediate recall: Word Learning Task (WLT) immediate recall; mDelayed recall: WLT Delayed recall; Cognitive
trajectory: high performance (1) to moderately altered (4); ϮP < 0.05/20 was considered as statistically significant.
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studies (23, 41, 89), we demonstrated that cognitive
performance of siblings was between those of
patients and controls indicating a parallel between
cognitive performance and familial liability. Sub-
typing cognitive proﬁle of unaﬀected siblings may
also provide insight to identify familial groups with
high-risk for developing psychosis and initiate
preventive strategies targeting healthy siblings.
Although not investigated in the present study,
adding genetic markers may unravel additional
cognitive subtypes given that cognitive traits are
heritable. Neurocognitive measures have been pro-
posed as one of the reliable endophenotypic mark-
ers of liability for schizophrenia, as cognitive
deﬁcits are transmitted within families of a patient
with schizophrenia (40, 41). Therefore, the subtyping
of cognitive trajectories in our study may provide
insight for determining possible endophenotypic
markers associated with schizophrenia and future
genetic analyses. Identifying distinctive cognition
subtypes may also be helpful to predict variation in
clinical and functional outcomes. In addition, iden-
tifying meaningful subtypes lends support to
develop group-based diagnostic criteria for cogni-
tive alteration. Moreover, given that not all
patients or siblings develop cognitive alteration
(30.5% patients vs. 61.8% siblings), identifying
subgroups of individuals is helpful for personalized
medicine to provide individualized evidence-based
interventions rather than ‘one-size-ﬁts-all’ approach,
such as cognitive remediation therapy, cognitive
adaption training, and medication therapy to
improve cognitive performance (19). In this study,
we proved that about one-third of siblings cognitive
trajectory predicted by patients cognitive trajectory
which can be applied in clinical utility on an individ-
ual dyad level though further investigation is
required on genetic, sociodemographic, and environ-
mental factors that aﬀect cognitive performance.
Furthermore, the present study showed that clinical
characteristics (i.e., subclinical psychotic experiences
in siblings, and psychotic symptoms in patients) and
premorbid functioning were poor in moderately to
severely altered subgroups, which shades light to
understand the pathophysiologic mechanisms of
cognitive alteration in schizophrenia.
Cognitive performance of a large number of
patients with non-aﬀective psychosis, their unaf-
fected siblings, and healthy controls was followed
for 6 years using a comprehensive neurocognitive
battery, which can be useful to ensure the clinical
and cognitive validity of trajectories. We included
patients and more than one siblings within the same
family to investigate the joint cognitive trajectory
of patients and siblings. Moreover, the study pro-
vided considerable evidence that siblings’ cognitive
alteration may be predicted by the diﬀerent cogni-
tive proﬁles of their probands. A methodological
strength of the current study was that we used
drop-out modeling within the same model as the
group-based trajectory modeling (70) to identify
the long-term cognitive trajectories. Other studies
did not take into account the drop-out modeling of
the dependency of cognitive functioning with the
function of several time points (75, 83, 84).
Some limitations of this study should also be
mentioned. First, even though the drop-out model-
ing analysis showed the absence of dependency of
cognitive functioning at previous assessments both
in patients and unaﬀected siblings, attrition bias
may still be evident. Second, we found that the pre-
diction of the high cognitive performer group of
patients on a moderate group of siblings was
ambiguous and unstable due to low frequency.
Third, strong associations between the patient’s
cognitive performance and their siblings’ cognitive
performance may not be claimed based on the sib-
pair analysis. Fourth, generating cognition com-
posite score instead of using multivariate cognitive
tests may have an impact on ﬁnding meaningful
trajectory. Fifth, this study used eight neurocogni-
tive tests; therefore, including other tests may lead
to diﬀerent trajectories with diﬀerent predictions.
Finally, the eﬀect of cognitive trajectories on clini-
cal and functional outcomes was not investigated.
In conclusion, our ﬁndings conﬁrmed that cogni-
tive functioning in patients with psychotic disorder
and their unaﬀected siblings is heterogeneous. We
demonstrated that the cognitive performance of
unaﬀected siblings is situated between that of the
patients and the healthy controls. We identiﬁed ﬁve
distinct cognitive trajectories in patients and four
trajectories in siblings, which remained stable during
6-year follow-up. These trajectories are validated by
observing the associations with external factors,
such as sociodemographic, (subclinical) psychotic
experiences, and premorbid functioning. Moreover,
patients cognitive subtypes signiﬁcantly predicted
the sibling subtypes highlighting the heritability of
cognition. The study also supports neurocognitive
trajectories as a valuable endophenotypic marker.
This proﬁling approach warrants further evaluation
in future molecular studies as well as in studies pre-
dicting functional and clinical outcomes.
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